Joanne Donovan Sells 50,000 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock

Key Points

• CMO Joanne Donovan sold 50,000 shares at an average price of $38.57 for roughly $1.93M, leaving her with 4,367 shares — a ~91.97% reduction in ownership, according to an SEC filing.
• Shares traded up 22.4% to $38.50 on heavy volume (3.71M vs. average 992.9k), valuing Edgewise at about $4.14B and near its 52‑week high (~$39.96).
• Analysts are mixed but the consensus is a Moderate Buy with an average price target of $38.13; JPMorgan raised its target to $45 while other firms range from sell to strong buy.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 50,000 shares of the firm's stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $38.57, for a total value of $1,928,500.00. Following the completion of the sale, the chief marketing officer owned 4,367 shares of the company's stock, valued at approximately $168,435.19. This represents a 91.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Edgewise Therapeutics Trading Up 22.4%

Shares of Edgewise Therapeutics stock traded up $7.05 during trading on Tuesday, hitting $38.50. 3,712,147 shares of the stock traded hands, compared to its average volume of 992,884. The stock's fifty day simple moving average is $31.11 and its 200 day simple moving average is $26.36. Edgewise Therapeutics, Inc. has a 52-week low of $12.15 and a 52-week high of $39.96. The firm has a market cap of $4.14 billion, a P/E ratio of -23.70 and a beta of 0.25.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.04). As a group, equities analysts expect that Edgewise Therapeutics, Inc. will post -2.16 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on EWTX shares. Wedbush reiterated an "outperform" rating and set a $32.00 price target on shares of Edgewise Therapeutics in a report on Tuesday, March 17th. JPMorgan Chase & Co. increased their price target on Edgewise Therapeutics from $34.00 to $45.00 and gave the company an "overweight" rating in a research report on Tuesday, March 17th. Raymond James Financial set a $46.00 price objective on Edgewise Therapeutics in a report on Tuesday, March 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Edgewise Therapeutics in a report on Monday, April 20th. Finally, Wall Street Zen downgraded Edgewise Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 28th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $38.13.

Institutional Trading of Edgewise Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Seven Fleet Capital Management LP bought a new position in Edgewise Therapeutics during the 4th quarter valued at $50,000. Jones Financial Companies Lllp acquired a new stake in shares of Edgewise Therapeutics in the first quarter worth $47,000. Bessemer Group Inc. boosted its position in shares of Edgewise Therapeutics by 1,170.3% in the third quarter. Bessemer Group Inc. now owns 2,350 shares of the company's stock worth $38,000 after buying an additional 2,165 shares during the period. Steward Partners Investment Advisory LLC boosted its position in Edgewise Therapeutics by 23.9% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company's stock valued at $71,000 after purchasing an additional 550 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in Edgewise Therapeutics during the second quarter valued at $45,000.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc NASDAQ: EWTX is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise's pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.